Profitability Metrics

Gross Margin
16.82%
Operating Margin
10.07%
Net Margin
6.71%

Efficiency Metrics

Revenue per Expense Ratio
1.11
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
15.88%
Income Tax Rate
25.40%
EPS
5.9800000000

Balance Sheet Analysis

Current Ratio
1.25
Cash Ratio
0.31
Working Capital
$269.89M
Debt to Equity
0.90
Debt to Assets
37.31%
Equity Ratio
41.24%

Cash Flow Analysis

Operating Cash Flow Ratio
13.48%
Free Cash Flow Ratio
8.64%
CapEx to Revenue
4.84%
Dividends Paid
$123.32M
Stock Buybacks
$288.02M
Total Shareholder Returns
$411.34M
Cash Position Change
128.09%

Key Takeaways (2023 FY)

  • Revenue declined by 14.653336950926%, indicating potential market challenges
  • Increased dividend payments by 37.24%

Detailed Growth Metrics

Core Performance

Revenue
-14.65%
Net Income
-38.67%
EPS
-32.43%
Operating Income
-33.89%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-82.03%
Operating Cash Flow
4.34%
Free Cash Flow
5.66%

Balance Sheet Health

Assets
14.13%
Debt
35.61%
Book Value per Share
9.44%
Inventory
-0.90%

Shareholder Returns

Dividends per Share
37.24%
Shares Outstanding
-3.86%

Long Term Trends

3Y Revenue/Share
106.33%
5Y Revenue/Share
104.74%
3Y Dividend/Share
79.72%
5Y Dividend/Share
132.11%